Vaxcyte, Inc.
Vaxcyte is a vaccine innovation company dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella to protect every child born and every adult at risk across the globe. They leverage advanced chemistry and synthetic techniques, including a cell-free protein synthesis platform, to develop high-fidelity, broad-spectrum vaccines. Their pipeline includes VAX-31 and VAX-24, which are designed to improve upon existing pneumococcal vaccines, as well as candidates targeting Group A Strep, periodontitis, and Shigella. Vaxcyte aims to re-engineer how vaccines are made to overcome limitations of conventional approaches.
Industries
Nr. of Employees
large (251-1000)
Vaxcyte, Inc.
Products
31-valent pneumococcal conjugate vaccine candidate (adult and infant programs)
A multivalent pneumococcal conjugate vaccine candidate engineered to expand serotype coverage for prevention of invasive pneumococcal disease in adults and infants; advanced into Phase 3 adult program and Phase 2 infant studies.
24-valent pneumococcal conjugate vaccine candidate (infant program)
A 24-valent pneumococcal conjugate vaccine candidate in Phase 2 infant studies designed to increase serotype coverage and address serotypes associated with high case-fatality and antibiotic resistance.
Group A Streptococcus conjugate vaccine candidate (preclinical)
A preclinical conjugate vaccine candidate intended to provide broad, boostable and durable protection against multiple subtypes of Group A Streptococcus.
Therapeutic periodontitis vaccine candidate (preclinical)
A therapeutic vaccine program targeting a keystone periodontal pathogen, leveraging cell-free expression to produce high-fidelity protein antigens aimed at preventing or treating periodontitis.
Shigella vaccine candidate (preclinical)
A preclinical vaccine program developing multivalent Shigella vaccine constructs intended to prevent dysentery and shigellosis, supported in part by public research grants.
31-valent pneumococcal conjugate vaccine candidate (adult and infant programs)
A multivalent pneumococcal conjugate vaccine candidate engineered to expand serotype coverage for prevention of invasive pneumococcal disease in adults and infants; advanced into Phase 3 adult program and Phase 2 infant studies.
24-valent pneumococcal conjugate vaccine candidate (infant program)
A 24-valent pneumococcal conjugate vaccine candidate in Phase 2 infant studies designed to increase serotype coverage and address serotypes associated with high case-fatality and antibiotic resistance.
Group A Streptococcus conjugate vaccine candidate (preclinical)
A preclinical conjugate vaccine candidate intended to provide broad, boostable and durable protection against multiple subtypes of Group A Streptococcus.
Therapeutic periodontitis vaccine candidate (preclinical)
A therapeutic vaccine program targeting a keystone periodontal pathogen, leveraging cell-free expression to produce high-fidelity protein antigens aimed at preventing or treating periodontitis.
Shigella vaccine candidate (preclinical)
A preclinical vaccine program developing multivalent Shigella vaccine constructs intended to prevent dysentery and shigellosis, supported in part by public research grants.
Services
Collaborative vaccine research partnerships
Collaborations with external organizations to jointly develop vaccine candidates and advance preclinical and clinical programs.
Collaborative vaccine research partnerships
Collaborations with external organizations to jointly develop vaccine candidates and advance preclinical and clinical programs.
Expertise Areas
- Conjugate vaccine design
- Cell-free antigen expression
- Clinical trial management (Phase 1–3)
- Biologics process development and scale-up
Key Technologies
- Cell-free protein synthesis
- Site-specific conjugation chemistry
- Non-native amino acid click chemistry
- Polysaccharide-protein conjugation